Early detection of complications during immunotherapy
Part of Blood & lymphatic, Cancer clinical trials.
This trial uses special equipment to watch for early side effects in people getting CAR T-cell therapy or bispecific antibodies for blood cancers, like lymphoma. It aims to catch problems early so they can be treated faster.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a blood cancer such as lymphoma
- You are scheduled to receive CAR T-cell therapy or bispecific antibodies
- You are not pregnant
- You do not have a pacemaker
- You are not allergic to the equipment materials
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients with relapsed or hard-to-treat B-cell lymphoma who are receiving CD19-directed CAR T cell therapy. Researchers collect blood and tissue samples to better understand each patient's unique risk profile, aiming to improve how the treatment is monitored and managed.
This study looks at how people with blood cancers do after they receive CAR-T therapy, radiation therapy, and/or bispecific therapy. It may help doctors understand which treatment combinations work best and what side effects to expect.
This study looks at tissue samples from adults who are receiving CAR-T cell therapy for blood-related conditions. It aims to learn more about how CAR-T works and what changes happen in the body, which may help improve future care.
This study uses blood tests and brain imaging to better understand and predict nerve-system side effects that can happen after CAR T-cell treatment. It may help doctors spot people at higher risk sooner and guide safer care.
This trial tests if a spinal injection of three common chemotherapy drugs can reduce or prevent serious brain and nerve side effects in people receiving CAR-T cell therapy for cancer.
This trial tests a new type of cell therapy (CAR T) that targets two markers on lymphoma cells, CD19 and CD22. It is for people with aggressive B-cell lymphoma that has not responded to standard treatments.
Hear when a new Hematologic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.